Log Type Authored on Log Message Log Node Authored by
Newsletter sent Newsletter sent to:tyoun@dumc.or.kr Gäst
Newsletter sent Newsletter sent to:tilde0207@gmail.com Gäst
Newsletter sent Newsletter sent to:jo-song94@hanmail.net Gäst
Newsletter sent Newsletter sent to:lalumiere72@gmail.com Gäst
Newsletter sent Newsletter sent to:gsooklee@gmail.com Gäst
Newsletter sent Newsletter sent to:korea@progress.im Gäst
Newsletter sent Newsletter sent to:kangzam@hanmail.net Gäst
Newsletter sending Sending to 474 Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Gäst
Newsletter sent Newsletter Test sent to:jinc@lundbeck.com,lily@lundbeck.com Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
User created User created Gäst
Newsletter opened Opened Gäst
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%97%A5%E6%9C%AC%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E3%82%B9%E3%83%86%E3%82%A3%E3%82%B0%E3%83%9E%E3%81%8A%E3%82%88%E3%81%B3%E3%81%9D%E3%81 Gäst
User created User created Gäst
OWA Status Updating trust level from 1 to 2 Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
Newsletter subscribed Newsletter subscribed - Progress in Mind Brazil newsletter Gäst
User created User created Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
OWA Status Updating trust level from 1 to 2 Gäst
Log Type Authored on Log Message Log Node Authored by
Newsletter sent Newsletter sent to:tyoun@dumc.or.kr Gäst
Newsletter sent Newsletter sent to:tilde0207@gmail.com Gäst
Newsletter sent Newsletter sent to:jo-song94@hanmail.net Gäst
Newsletter sent Newsletter sent to:lalumiere72@gmail.com Gäst
Newsletter sent Newsletter sent to:gsooklee@gmail.com Gäst
Newsletter sent Newsletter sent to:korea@progress.im Gäst
Newsletter sent Newsletter sent to:kangzam@hanmail.net Gäst
Newsletter sending Sending to 474 Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Gäst
Newsletter sent Newsletter Test sent to:jinc@lundbeck.com,lily@lundbeck.com Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
User created User created Gäst
Newsletter opened Opened Gäst
Newsletter clicked Clicked https://japan.progress.im/ja/content/%E6%97%A5%E6%9C%AC%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E7%B2%BE%E7%A5%9E%E7%96%BE%E6%82%A3%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E3%82%B9%E3%83%86%E3%82%A3%E3%82%B0%E3%83%9E%E3%81%8A%E3%82%88%E3%81%B3%E3%81%9D%E3%81 Gäst
User created User created Gäst
OWA Status Updating trust level from 1 to 2 Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
Newsletter subscribed Newsletter subscribed - Progress in Mind Brazil newsletter Gäst
User created User created Gäst
Newsletter opened Opened Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
Newsletter opened Opened Novos medicamentos têm como alvo a CGRP e seus receptores Gäst
OWA Status Updating trust level from 1 to 2 Gäst